Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sorin's Paradym 8770 sonR cardiac resynchronisation defibrillator:

This article was originally published in Clinica

Executive Summary

Sorin has CE marked its Paradym 8770 sonR cardiac resynchronisation therapy defibrillator (CRT-D) for sale in Europe. The system employs sonR technology, a sensor that adjusts CRT delivery based on haemodynamic response - as opposed to conventional CRT-D devices which monitor the electrical activity of the heart. The Milan, Italy-based company claims that Paradym sonR is the first device delivering continuous management of resynchronisation therapy during heart failure patients' everyday life. Sorin's cardiac rhythm management business has also initiated a 150-patient European clinical trial of the device. According to the European Society of Cardiology (ESC) and the American Heart Association (AHA), more than 10 million Europeans and five million Americans suffer from heart failure.

You may also be interested in...

P&G: Sales Growth Strongest When Rising Tide Floats All Competitors Across All Categories

P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts